Each 1 ml contains Tylosin Tartrate 200mg.
Treats shipping fever, pneumonia, foot rot, calf diphtheria, metritis in beef cattle and non-lactating dairy cattle. Treats mycoplasmal swine arthritis, pasteurella pneumonia, erysipelas, acute swine dysentery in swine.
Tylosin is thought to have the same mechanism of action as ery�thromycin (binds to 50S ribosome and inhibits protein synthesis) and exhibits a similar spectrum of activity. It is a bacteriostatic antibiotic. For more specific information on or�ganisms that tylosin is usually active against, refer to the erythromycin monograph just prior to this one. Cross resistance with erythromycin occurs.
Usage and administration:
Beef and non-lactating dairy cattle: Inject IM 8 mg per pound of body Weight (1 mL per 25 pounds) once daily. Treatment should be continued 24 hours after symptoms of the disease have stopped, not to exceed 5 days. Do no inject more than 10 ml per injection site.
Swine: Inject IM 4 mg per pound of body weight (1 mL per 50 pounds) twice daily. Treatment should be continued 24 hours after symptoms of the disease have stopped, not to exceed 3 days. Do not inject more than 5 mL per injection site.
Side effect and contraindication: N/A
Do not mix Tylosin Injection with other injectable solution as this may cause precipitation of the active ingredient. Do not administer to horses or other equine species. Injection of tylosin in equines has been fatal.
Discontinue use in cattle 21 days before slaughter. Discontinue use in swine 14days before slaughter.
Storage and expired time:
Put in a cool dry place away from direct sunlight. Store in a cool, dry place under 22 �C, away from direct sunlight.
Cancer Blueprint Day
The Keshe Foundation is proud to announce a new cancer solution breakthrough!
It is simple, inexpensive, and accessible to everyone.
Imagine there is a technology, which can not only balance your physical body, but also helps you finding out the roots of your own disease or the one of your patients! This technology, this knowledge is already available and as in every section of the Keshe Foundation, the knowledge is free for everyone, you can use it for yourself!
Nuclear Engineer Mehran Tavakoli Keshe will unveil for the first time to the public the new revolutionary cancer processing by the use of new plasma science.
Full clinical trial case with breast cancer will be presented by the doctors using this revolutionary processing.
Doctors, scientists, professionals, and press are invited to watch and participate in the presentation and examine the data presented.
Detailed information was released on Tuesday April 18th, 2017 during the Cancer Blueprint Day, starting at:
09:00 AM CET Rome, IT
03:00 AM EDT New York, US
12:00 AM PDT Los Angeles, US
03:00 PM HKT Hong Kong, HK
05:00 PM AET Sydney, AU
Disclaimer: Every individual and company must take full responsibility for applying this new knowledge shared freely from the Keshe Foundation.
Simultaneous live streaming was done at:
Zoom: https://spaceshipinstitute.zoom.us/j/939474503 (MIC POSSIBLE!)
Find more of our Public Teachings on Keshe plasma science and technology here: https://www.youtube.com/c/KeshefoundationOrg/playlists
Become a student at the world’s first Spaceship Institute! For only 100 euros, you get a full calendar year of access to live and recorded private teachings. There are thousands of hours of extended private teachings stored in our private portal at the Keshe Foundation Spaceship Institute (KF SSI).
Apply today to become a student at the KF SSI.
More information is available at our website https://kfssi.org
Direct link to Student Application Form is available at https://kfssi.org/study-apply